BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012; 18(16): 1933-1939 [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933]
URL: https://www.wjgnet.com/1948-5182/full/v18/i16/1933.htm
Number Citing Articles
1
JIAN HUANG, GUOZHEN YANG, YUNZHU HUANG, WEIYING KONG, SHU ZHANG. 1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1)Molecular Medicine Reports 2016; 13(2): 1373 doi: 10.3892/mmr.2015.4676
2
Kazuto Tajiri, Kengo Kawai, Masami Minemura, Satoshi Yasumura, Ayumu Hosokawa, Hideto Kawabe, Gakuto Tomizawa, Toshiro Sugiyama. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracilHepatology Research 2015; 45(7): 755 doi: 10.1111/hepr.12417
3
Bohuslav Melichar, Josef Dvorak, Alexander Ferko, Katerina Kamaradova, Antonin Krajina. Hepatic arterial infusion in hepatocellular carcinoma: a single center experienceBiomedical Papers 2015; 159(1): 139 doi: 10.5507/bp.2014.054
4
Hyung Joon Yim, Sang Jun Suh, Soon Ho Um. Current management of hepatocellular carcinoma: An Eastern perspectiveWorld Journal of Gastroenterology 2015; 21(13): 3826-3842 doi: 10.3748/wjg.v21.i13.3826
5
Myung Jin Oh, Heon Ju Lee, Si Hyung Lee. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapyClinical and Molecular Hepatology 2013; 19(3): 288 doi: 10.3350/cmh.2013.19.3.288
6
Baojiang Liu, Xu Zhu, Song Gao, Jianhai Guo, Xiaodong Wang, Guang Cao, Linzhong Zhu, Peng Liu, Haifeng Xu, Hui Chen, Xin Zhang, Shaoxing Liu, Fuxin Kou. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinomaJournal of Interventional Medicine 2019; 2(2): 91 doi: 10.1016/j.jimed.2019.07.006
7
Kenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, Shinsuke Uchikawa, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Keiichi Masaki, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Hirotaka Kohno, Hiroshi Kohno, Takashi Moriya, Michihiro Nonaka, Hideyuki Hyogo, Yasuyuki Aisaka, Kazuaki Chayama. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory statusJournal of Gastroenterology and Hepatology 2018; 33(10): 1780 doi: 10.1111/jgh.14152
8
Ngoc Bich Vu, Tam Thanh Nguyen, Long Cong-Duy Tran, Cong Dinh Do, Bac Hoang Nguyen, Ngoc Kim Phan, Phuc Van Pham. Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like propertiesCytotechnology 2013; 65(4): 491 doi: 10.1007/s10616-012-9511-9
9
Masafumi Ikeda, Shuichi Mitsunaga, Satoshi Shimizu, Izumi Ohno, Hideaki Takahashi, Hiroyuki Okuyama, Akiko Kuwahara, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Mitsuo Satake, Yasuaki Arai, Takuji Okusaka. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolizationJournal of Gastroenterology 2014; 49(5): 932 doi: 10.1007/s00535-013-0853-7